Biotechnology company Dendreon Corp. (NASDAQ: DNDN) on Thursday named former Bayer executive Hans Bishop chief operating officer, making him responsible for leading the commercial launch of the potential prostate cancer treatment Provenge, according to Associated Press.
The Penny Stock Picks, an online financial publication, provides investors timely stock market alerts.
Sign Up Today for our Free Newsletter
Bishop will start Jan. 4, Dendreon said in a statement. He served most recently as president of Bayer's specialty medicine business and was responsible for oncology, hematology and neurology products.
Dendreon said last month the Food and Drug Administration will make a regulatory decision on Provenge by May 1.
The drug works as a vaccine to stimulate the body's immune system to fight the cancer, but it is given as a treatment rather than as a preventive measure.
Sign Up for The Penny Stock Picks' FREE Penny Stock Newsletter.
The Penny Stock Picks is a financial website and independent electronic publication that provides information and free penny stock alerts on selected publicly traded companies. We also track small cap companies that may be positioned to break out.
The Penny Stock Picks is not a registered investment advisor or broker-dealer. Please do your own Due Diligence before investing in any of the stocks mentioned above. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer